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IMMUNE CHECKPOINT EXPRESSION IN SIV-INFECTED RHESUS 
MACAQUES TREATED WITH TLR7 AGONISTS 
RIDDHI SHAH 
ABSTRACT 
 While the human immunodeficiency virus (HIV) can be managed with 
antiretroviral therapy (ART), there is no cure for the disorder. If ART is discontinued, viral 
RNA levels rapidly increase in most individuals due to the presence of a cell-mediated 
hidden replication competent viral burden known as the viral reservoir. In order to 
successfully cure this disease, a mechanism to eliminate the viral reservoir must be 
developed. Preliminary research completed using a toll-like-receptor agonist 7 (TLR7) has 
shown favorable results supporting this goal. In a simian immunodeficiency virus (SIV) 
model, dosing rhesus macaques (RMs) with TLR7 agonists resulted in the development of 
controlled viremia. A controlled RM is a SIV positive animal that is able to maintain an 
undetectable viral load without continued therapeutic intervention. In cases of controlled 
SIV/HIV, viral RNA no longer replicates despite the discontinuation of all treatment. This 
implies that the viral reservoir is either completely eliminated or severely reduced.  
In this study, we quantified expression levels of several immune checkpoint and 
activation markers including CD69, CD39, CXCR5, TCF7, PD-1, PD-L1, TIGIT, CTLA-
4, Tim-3, and Lag-3 on isolated peripheral blood mononuclear immune cells (PBMCs) 
[including CD4+ T cells, CD8+ T cells, natural killer (NK) cells, and B cells] in both 
controlled and non-controlled RMs. Our goal was to identify possible mechanisms by 
which controlled RMs are able to successfully modulate the host immune response after 
 
 v
discontinuing TLR7 agonist treatment. The subjects each received one of two different 
TLR7 agonists (GS-9620 and GS-986). Isolated peripheral blood mononuclear cells 
(PBMCs) were obtained from two controlled RMs and two non-controlled RMs. Samples 
were analyzed using flow cytometry to identify and quantify levels of markers above.  
Expression levels of PD-1 and PD-L1 were elevated in PBMCs obtained from non-
controlled RMs when compared to levels seen in controlled RMs. In contrast, levels of 
TIGIT and CTLA4 were downregulated in samples obtained from the controlled RMs. This 
suggests that immune checkpoint markers responsible for viral control and SIV/HIV 
pathogenesis have different functional roles. Additionally, the controlled RMs showed high 
expression of CD69 and CD39 on B cells and increased levels of CXCR5 on CD4+ T cells.  
This suggests that newly activated B cells likely contribute to the observed improvements 
in immune function.  
The results obtained provide favorable support for the potential role of immune 
checkpoint blockade as an HIV-specific immunotherapy that may contribute to the 
development of a controlled population. However, it is worthwhile to note that this study 
was completed using a relatively small sample size (n=4). Thus, interpretations of the 
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Human immunodeficiency virus (HIV) 
Using electron microscopy, scientists were first able to identify the human 
immunodeficiency virus (HIV) in 1983, though it was not officially named until 1986 
(Greene et al., 1986). This 9-kb RNA virus would go on to impact international 
conversation in an immeasurable way as scientists and members of the public studied this 
new disease (Greene et al., 1996). The 25 million deaths worldwide attributed to HIV are 
secondary to reduced immune function and through associated comorbid conditions 
including HIV-associated neurocognitive disorders and cancers (Sharp et al., 2011; Beck 
et al., 2018; Dandapani et al., 2010). While therapeutic research has dramatically increased 
and improved the lifespan of HIV+ individuals, a curative treatment does not yet exist 
(Evans et al., 2013). Much of the research conducted today is done on a simian 
immunodeficiency virus (SIV) nonhuman primate model (Evans et al., 2013). 
SIV Model 
Preliminary research completed using an SIV model for HIV allowed scientists to 
better understand events that contributed to viral transmission and disease pathogenesis 
(Evans et al., 2014). Years of research resulted in the development of a well-controlled, 
highly characterized, and easily reproducible non-human primate model for HIV (Beck et 
al., 2018). Interestingly, though African monkeys are the natural host of SIV, they are 
typically non-pathogenic (reviewed in Evans et al., 2014). As such, researchers today 
frequently utilize SIV-infected Asian macaques in their work. Macaques share many 
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physiologic and immunologic characteristics with humans. Both SIV and HIV are chronic 
progressive infections. Kinetically, both disorders can be characterized by an acute peak of 
viremia followed by decline. Furthermore, both non-human primates and humans develop 
a viral reservoir shortly after acute infection. The viral reservoir is a pool of latent infected 
cells and is frequently studied. Using a non-human primate model allows researchers to 
study the molecular characteristics of the reservoir and to test the efficacy of aggressive 
reservoir-targeted therapeutic treatments while tightly regulating a number of experimental 
parameters (dose frequency, duration, route).  
HIV Viral Life Cycle 
The HIV virus will first enter a cell when a cell-surface envelope glycoprotein binds 
to a receptor (CCR5 or CXCR4) (reviewed in Goodsell et al., 2015). The resulting 
conformational change allows the virus to fuse through the targeted cell’s membrane. 
Inside the cell, the viral RNA will be transcribed into DNA upon activation of a reverse 
transcription complex. Through integration, the newly replicated viral DNA inserts itself 
into the host cell’s DNA. The viral particle will assemble and bud from the cell and enter 
the bloodstream.  
Stages of Infection  
It has been well established that there are three stages of HIV infection. After initial 
infection, the virus will predominantly target and infect CD4+ T cells. A patient will likely 
be symptomatic within one to six weeks, presenting with signs of fever, fatigue, and weight 
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loss as their viral load rapidly increases (reviewed in Aavani et al., 2019). The 
concentration of CD4+ T cells will decline while CD8+ T cells and antibody levels increase 
and attempt to fight the viral infection. This acute stage of infection will last for 
approximately 14 days. For the next 6 to 15 years, a patient will remain in an 
“asymptomatic stage.” During this stage, there is a slower decline in CD4+ T cells. 
However, the HIV particle is still actively targeting lymphoid tissue which results in rapid 
lymphocytic degradation and regeneration. A patient’s viral load, or measured number of 
viral particles found in plasma, is approximately 104 copies per milliliter of plasma during 
the asymptomatic stage. In the third and final stage of infection, a patient has progressed 
to acquired immunodeficiency disorder syndrome (AIDS). All immune responses rapidly 
decline, including antibody production, CD8+ T cell function, and CD4+ T cell 
concentrations. At this stage, additional comorbid conditions will likely develop and 
consequently, death is imminent as the immune system struggles to successfully target 
invading pathogens. 
Current Treatment Options  
Preventing Viral Replication (ART) 
Current treatment options include antiretroviral therapy (ART), a combination 
therapy that can result in the reduction of viral RNA to an undetectable level while also 
improving immune system function by increasing CD4+ T cell count (reviewed in Pau et 
al., 2014). ART functions by stopping viral replication during one of the six stages of the 
HIV life cycle. The effects of different agents that are commonly found in a therapeutic 
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cocktail are detailed in Table 1. Though ART has successfully prolonged survival, it is not 
a curative treatment.  
Therapeutically Targeting the Viral Reservoir 
A viral reservoir consists of a pool of HIV-1 viral particles that reside in CD4+ T-
cells and likely forms during peak viremia (Liu et al., 2020; Thompson et al., 2017). 
Currently, there is a limited understanding of the expression level of surface proteins on 
reservoir cells, though this is an important area of study that can potentially lead to a 
curative treatment for HIV (Liu et al., 2020). This reservoir of cells often forms in well-
protected lymphoid tissues which create an additional physical and molecular barrier 
against therapeutic agents (Cory et al., 2019). In addition, the reservoir has a half-life of 
approximately 44 months, requiring over 70 years total to decay to zero without therapeutic 
intervention (Liu et al., 2020).  
 
Since these latent cells are not effectively treated by ART, the viral reservoir 
maintains a persistent repository of viral particles (Aawani et al., 2019; Pau et al., 2014). 
These latent cells can reactivate at any time. If ART is discontinued or temporarily paused, 
an otherwise undetectable patient will likely start presenting with detectable plasma levels 
of HIV due to clonal expansion of HIV-1 infected cells in the viral reservoir (Pau et al., 
2014). Many factors can contribute to the discontinuation of ART therapy, including 
forgetting to take medications, travel, psychological disturbances, as well as limited access 
to healthcare (Shubber et al., 2016). Thus, studying reservoir targeted eradication therapies 
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is critical in developing a curative treatment for HIV. Identifying markers that are present 
on cells in the viral reservoir is an important step in this process.  
 
Currently, the viral reservoir is not being treated by any publicly available 
therapeutic treatments. In addition to the therapies preventing viral replication (top of 
Table 1), there are three primary experimental categories of therapeutic treatments to target 
the viral reservoir (bottom of Table 1). The first method is informally referred to as “kick 
and kill” (reviewed in Cory et al., 2019). Cells in the reservoir are re-activated (“kicked”) 
and the newly activated virus is subsequently destroyed by the immune system (“killed”). 
Histone deacetylate inhibitors (HDACs) are frequently studied as a potential therapeutic 
agent that can support the “kick and kill” model. This model can lead to a sterilizing cure 
for HIV, which implies that all detectable viral particles are eliminated.  A second strategy 
that can lead to a functional cure for HIV is to prevent reservoir cells from reactivating, 
which effectively eliminates any potential functionality of the hidden HIV particles without 
the use of ART. At present, Tat inhibitors are being evaluated to validate this model. 
Finally, developing mechanisms to increase the concentration of ART in well protected 
lymphoid tissue can result in an overall decrease in latent HIV concentrations. Presently, 
P-gp inhibitors are being studied to support this theory. Though the discussed options are 





Table 1: Molecular agents commonly used or studied in HIV therapeutic development 
HIV Life Cycle Drug Class Function 






Phosphorylated NRTIs block the conversion of 
viral RNA into double stranded DNA by 
incorporating into the nucleotide analog and 





Inhibits the function of reverse transcriptase by 
changing the structural conformation of the enzyme 
(Pau, 2014) 
Protease Inhibitors (PI) Halts the function of HIV proteases which prevents 
the formation of mature virions (Pau, 2014) 
Integration Integrase Strand 
Transfer Inhibitors 
(INSTI) 
Prevents the formation of covalent bonds between 
host and viral DNA by blocking the integrase 
enzyme (Pau, 2014) 
Cell entry  
 
CCR5 Antagonist Binds to CCR5, a cell membrane receptor, which 
effectively prevents HIV from invading a CD4 T 
cell (Pau, 2014) 
Fusion Inhibitor  Binds to gp41 (glycoprotein) which prevents the 
fusion of the viral and cellular membrane (Pau, 
2014)  
Targeting the Viral Reservoir 




Reactivate latent CD4+ T cells and increase HIV 
RNA concentrations allowing the virus to be 
targeted by the immune system (Archin, 2017 and 
Cory, 2019) 
TAT Inhibitors  Inhibits the function of HIV transcription factors in 
latent CD4+ T cells (Cory, 2019) 
P-gp Inhibitors Inhibits the function of P-glycoprotein, a drug 
efflux transporter, effectively allowing for ART 
agents to enter lymphoid tissues (Robillard, 2013 




Innate Immunity  
Host-genome encoded innate immune mechanisms are non-specific and include 
physical barriers, proteins, regulatory cytokines, chemokines, and other enzymes (Chaplin 
et al., 2006). The innate immune response to viral infection is triggered by binding between 
pathogen recognition receptors (PRRs) and pathogen associated molecular patterns 
(PAMPs) (Chaplin et al., 2006; Altfeld et al., 2015; Mogensen et al., 2010). Toll-like 
receptors (TLRs) are a family of PRRs that are essential in the human innate immune 
response (as reviewed in Morgenson et al., 2010). The ten identified TLRs that are 
membrane-bound receptors expressed on innate immune cells and function in recognizing 
broad categories of pathogenic material, including glycoproteins, lipoproteins, DNA, and 
RNA.  
 
This paper studied molecular changes in rhesus macaques (RM) after 
administration of a TLR7 agonists. TLR7 can be found in endosomal compartments of 
innate immune cells and recognize nucleic acids. Specifically, single-stranded viral RNA 
serves as a ligand for TLR7 and binding results in activation of the innate immune response 
(Diebold et al., 2004). HIV-1 encodes for several TLR7 activating ligands (Chang et al., 
2009). Once a ligand binds to the TLR-7 receptor, two transcription factors (nuclear factor 
kappa light chain enhancer of activated B cells and interferon regulatory factor 7) 
translocate to the nucleus and stimulate the production of cytokines, including interferon 
alpha (Bam et al., 2016). After the cytokines bind to cytokine-specific receptors, the 
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production of a number of different antiviral proteins begin. Bam et al. (2016) found that 
GS-9620, an oral TLR-7 analog, induces the production of antiviral proteins, specifically, 
interferon alpha, that effectively stops HIV replication in PBMC at or prior to the reverse 
transcription step.  
 
A study conducted by Lim et al. (2018) on a non-human primate model 
demonstrated that administration of a TLR7 agonist can potentially serve as a “kick and 
kill” therapeutic agent. Treated subjects developed transient viral blips and head 
measurable increases in interferon-activated gene production. The increased immune 
response combined with induced transient viremia contributed to noticeable reductions in 
the viral reservoir of treated RMs. Thus, it is hypothesized that the TLR7 agonists used in 
this study may have a functional role in eliminating the viral reservoir. Additionally, the 
HIV set point, or the measured viral load after infection, decreased in RMs that were treated 
with TLR7 agonists. Two subjects were aviremic for >24 months after treatment 
discontinuation.   
Adaptive Immunity  
In contrast to the innate immune system, the adaptive immune system specifically 
targets invading antigens (reviewed in Chaplin et al., 2006; Molnar et al., 2012). Millions 
of different antigen receptors, known as T-cell receptors (TCRs), can be created using 
germline-encoded genes and are found on T-cells, a broad class of immune cells. The TCRs 
will recognize a class I or class II major histocompatibility complex (MHC) molecule. 
Class I MHC molecules are found on cell surfaces and express fragments of proteins that 
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are internalized in the cell. Class I molecules will bind to CD8+ T cells.  Class II molecules 
are found on antigen-presenting cells (including but not limited to dendritic cells and 
macrophages) and express fragments of extracellular proteins largely obtained from a 
pathogenic source. Class II molecules will bind to CD4+ T cells.  
 
When activated by MHC II binding, CD4+ T cells will become T helper cells which 
then stimulate B cells and cytotoxic T cells (CTLs) (reviewed in Molnar et al., 2012; Martin 
et al., 2018). B cells are white blood cells that will produce antibodies when activated. 
CTLs release cytokines that eventually lead to cellular apoptosis. When a CD8+ T cell 
binds to MHC I, it becomes a CTL and will induce cellular apoptosis. Naïve CD4+ and 
CD8+ T cells can further differentiate into memory T cells. Memory T cells have 
previously encountered an antigen and are able to mount an immediate immune response 
through rapid cell proliferation. There are two classes of memory cells: central memory 
(TCM) and effector memory (TEM). The classes differ in the cell surface markers they 
express. Central memory cells tend to possess surface markers that localize to secondary 
lymphoid organs (i.e. lymph nodes) and consequently, are thought to primarily function in 
fighting systemic infections. On the other hand, effector memory cells possess a large 
number of chemokine receptors that resultantly lead them to sites of inflammation. These 
cells are generally found in peripheral tissues and are more cytotoxic in nature than central 




A number of viruses have developed mechanisms to downregulate MHC I 
expression and thus, hamper the adaptive immune response (reviewed in Kerkau et al., 
1997). Though HIV-1 infection induces rapid proliferation of CD8+ T cells, infected cells 
are able to evade CD8+ T cell mediated destruction. HIV-1 encodes for a viral protein U 
gene which normally functions in facilitating the release of a HIV particle from cells. 
Kerkau et al. (1997) found that this gene additionally interferes in an early step of class I 
MHC molecular formation which results in a reduction of MHC I molecules on infected 
cells. Without MHC I, CD8+ T cells are unable to recognize HIV-infected cells and can no 
longer maintain normal destructive function.  
 
Interestingly, the innate immune system utilizes the same degradative effects to 
recognize and destroy infected cells (as reviewed in Molnar et al., 2012). Natural killer 
(NK) cells innate immune cells that induce apoptosis by releasing cytolytic granules. If an 
NK cell comes across a “healthy” cell with an MHC I molecule, it will ignore it and move 
on. However, if it comes across a cell that does not possess an MHC I molecule, it will 
operate under the assumption that the cell is infected and self-degraded its MHC I 
molecule. The NK cell will subsequently release function in destroying this cell.  
 
HIV actively targets and infects any cells that contain a CD4 receptor, including 
CD4+ T cells, macrophages, and monocytes (as reviewed in Aavani et al., 2019). However, 
the viral particle will predominantly target CD4+ T cells. As described above, CD4+ T 
cells have a critical role in the adaptive immune response as they are able to stimulate B 
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cells and CTLs. When CD4+ T cells are infected by the viral particle, they are no longer 
able to function as immune cells and instead primarily function in replicating the viral 
particle. However, if a CD4+ T cell is not infected by the virus, it attempts to maintain 
normal function and fight off the pathogenic infection. Aavani et al. (2019) developed a 
mathematical model of this conflicting dynamic and identified a gradually diminishing 
cyclical pattern. Because CTLs are stimulated by CD4+ T cells and viral load, they respond 
by destroying CD4+ T cells. Without CD4+ T cells to induce the production of CTLs, the 
overall concentration of these molecules decrease. In summary, the adaptive immune 
response is significantly limited in cases of HIV infection as both CD8+ T cell and CD4+ 
T cells are not able to maintain normal functioning.  
CD69 
Effector cells are plasma cells (which are derived from fully differentiated B cells) 
and CTLs (reviewed in Molnar et al., 2012; Janeway et al., 2005). Memory cells are able 
to rapidly differentiate into effector cells upon re-exposure to a pathogen. Additionally, 
upon activation, some naïve T cells will form into effector cells. The expression levels of 
many cell surface molecules will change after naïve or memory cells transition into effector 
cells. CD69 serves as an early activation marker and is one of the first cell surface markers 
displayed by CTLs and plasma cells.  In the innate immune system, CD69 also serves as 
an activation marker and is present on activated NK cells. This marker is exclusively seen 
on effector cells and will not be expressed on naïve or memory cells. The CD69 marker 
consists of a 24-kDa polypeptide with N-linked oligosaccharides and is a phosphorylated 
disulfide linked homodimer (Krowka et al, 1995). Using flow cytometry and CD69 
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antibodies, researchers are able to easily identify populations of activated CTLs, B cells, 
and NK cells.  
 
T cell Exhaustion  
Chronic viral infection results in the development of an exhausted lymphocytic 
state (Gupta et al., 2015). Typically, some effector T cells will form into memory T cells. 
However, in cases of T cell exhaustion, effectors cells are unable to form into memory cells 
and instead lose functionality and proliferative capabilities (reviewed in Khaitan et al., 
2011). Additionally, the effector cells that are present are no longer fully responsive to 
stimuli. Exhausted CD8+ T cells can be further divided into two classes which are 
categorized by the surface transcription factors they express (reviewed in Gupta et al., 
2015). CD8+ T cells that express the transcription factor T-bet are progenitor cells. 
Progenitor cells have not reached a state of terminal exhaustion and that can still proliferate 
into functioning CTLs, though the proliferative potential and effector functions may be 
markedly reduced than what can be observed in healthy individuals.  On the other hand, 
cells that express eomesodermin (eomes) in high concentrations have likely reached a stage 
of terminal exhaustion and cannot regain normal functionality. Both T-bet+ CD8+ T cells 
and Eomes+ CD8+ T cells express unique concentrations and compositions of inhibitory 




Immune Checkpoint Molecules  
  Immune checkpoint molecules are inhibitory receptors that are located on T cells. 
Immune checkpoint blockade therapies were first studied while evaluating mechanisms 
that induce T cell activation and have been found to have an important role in regulating 
the immune response (Wei et al., 2018). Exhausted T cells can be characterized by the 
expression of a number of inhibitory immune checkpoint molecules including PD-1, Lag3, 
Tim3, and CTLA4 on T cells (Khaitan et al., 2011). In cases of infection, blocking 
inhibitory immune checkpoint markers can potentially improve immune response as 
immune checkpoint mediated inhibitory signals directed at T-cells are no longer functional 
(Wei et al., 2018). Thus these markers can be used as a targeted immunotherapy in cases 
of chronic viral infection.  
 
Many forms of cancerous cells utilize immune checkpoint molecules to weaken the 
immune response (reviewed in Wykes et al., 2018). Currently, antibodies that directly 
target immune checkpoint markers expressed on exhausted cells are being used as a 
therapeutic treatment for cancer, with the hope of improving the immune response. In 
theory, blocking these markers can result in reversal of T cell exhaustion in chronic HIV 
infection.  It is important to note that experimental use of immune checkpoint inhibitors 
have occasionally been linked to retinal toxicity (in macaques), and autoimmune toxicities, 
including colitis, myocarditis, and pneumonitis. In addition, the use of immune checkpoint 
inhibitors is a costly endeavor. As such, before implementing the use of immune 
checkpoint inhibitors in HIV, additional studies need to be completed to identify specific 
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marker expression at various stages in the disease process. The next sections herein 
evaluate the structure and function of immune checkpoint molecules that are theorized to 
contribute to the HIV/SIV immune response, with special emphasis placed on T cell 
exhaustion. Immune checkpoint molecule expression levels in an SIV model are thought 
to mimic the expression levels seen in HIV+ samples. Thus, we will evaluate expression 
levels of each of the immune checkpoint markers discussed in SIV-infected rhesus 
macaques. 
PD-1 
PD-1 (programmed cell death protein 1) is a member of the cluster of differentiation 
28 (CD28) family (Akinleye et al., 2019). It is present on activated T cells and B cells and 
is encoded by the PDCD1 gene (Zheltkova et al., 2019; Akinleye et al., 2019). (reviewed 
in Akinleye et al., 2019). Tasuku Honjo discovered this immune checkpoint molecule in 
1992 while studying apoptotic immune cells (reviewed in Akinleye et al., 2019). He was 
able to successfully clone this 288-amino acid receptor from a murine model. In 1998, 
further studies were completed in a lupus-like murine model and it was found that PD-1 
negatively regulates immune responses (Okazaki et al., 2007). When a ligand (PD-L1 or 
PD-L2) binds to this receptor, the proliferative and effector functions of T cells decrease 
(Bekerman et al., 2019).  Most PD-1 research has focused on its roll e in cancer 
immunology, as it was found that tumors frequently evade T-cell mediated responses 




In models of untreated HIV, PD-1 was found to be upregulated in on central 
memory and regulatory CD4+ and CD8+ T cells (reviewed in Wykes et al., 2018). Though 
levels of PD-1 decrease after ART initiation, the overall expression level of this immune 
checkpoint remains elevated when compared to a HIV- individual. Time of initiation of 
ART does not seem to affect expression levels in anyway. Clinically, the elevated 
expression of PD-1 after initiation of ART has been linked to oxidized low-density 
lipoproteins which may increase a patients’ risk of stroke or vascular damage. At a 
molecular level, elevated levels of PD-1 are associated with shorter time to viral rebound 
after ART discontinuation.   
 
Previous research completed using an SIV model has shown that blocking PD-1 
resulted in an increased number of CD8+ T cells and improved functioning of these cells 
(Zheltkova et al., 2019; Wykes et al., 2018 Gupta et al., 2015). An expansion in CD8+ T 
cells is directly linked to reduction in the SIV RNA and prolonged survival (Zheltkova et 
al., 2019; Bekerman et al., 2019; Wykes et al., 2018). There were no adverse effects 
observed when administering anti-PD-1 therapy in an SIV model if the subject was on ART 
(Wykes et al., 2018). However, it is important to note that using PD-1 as a diagnostic or 
therapeutic marker is challenging as it has been found to be normally expressed on a 
number of a number of different cells, including up to 60% of a healthy individual’s 
memory CD8+ T cell population (Gupta et al., 2015).  In this thesis, we will quantify 
expression levels of PD-1 in TLR-7 treated SIV+ rhesus macaques. Based on the concepts 
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described above, we know that overexpression of PD-1 implies decreased immune 
function, specifically in CD8+ T cells.  
PD-L1 
Freeman et al. (2000) reported that programmed death ligand 1 (PD-L1) is 
expressed by antigen presenting cells and is a ligand for PD-1. Expression levels were 
predominantly seen on interferon γ stimulated human peripheral blood monocytes, human 
dendritic cells, murine dendritic cells, heart, and lung tissues. Freeman found that exposure 
to cytokines induced the upregulation of PD-L1 and B7-1 protein. B7-1 is a stimulatory 
protein that activates T cell function. Its counterpart, B7-2 is, is constitutively on 
monocytes but can be induced in other APCs (including B cells, dendritic cells, and 
macrophages). The balance between PD-L1 and B7-1/2 directly control the level of T cell 
activation.  Like PD-1, research with PD-L1 has primarily focused on cancer 
immunotherapy (Akinleye et al., 2019).  
 
In an ex-vivo model developed using HIV+ blood donors, using anti-PD-L1 
resulted in increased proliferation of CD4+ and CD8+ T lymphocytes (Zheltkova et al., 
2019). Since CD4+ T lymphocytes are targeted and killed by the HIV virus, increasing 
the functional concentration of CD4+ cells can result in viral expansion. Therefore, it is 
assumed that the viral load is reduced only if the number of activated CD4+ T cells 
remain below a specific threshold. In addition, while B-cells uncommonly express the 
PD-1 receptor, they too benefit from anti-PD-L1 (Akinleye et al., 2019). Reduced PD-
L1/PD-1 binding effectively reduces PD-1 mediated exhaustion in this cell population 
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(Zheltkova et al., 2019). B cell exhaustion presents in a very similar manner as T cell 
exhaustion, with exhausted B cells exhibiting decreased ability to proliferate in response 
to stimulation (Fauci et al., 2014).  The antibodies produced by the activated B cells can 
help neutralize the increased viral spread caused by the greater concentration of 
functional CD4+ T cells.  We will quantify PD-L1 expression in a TLR7 treated rhesus 
macaque model. After reviewing the factors addressed above, our assumption is that 
monkeys that exhibit better viral control will express lower levels of PD-L1.  
CXCR-5 
Chemokines are a family of cytokines that primarily function in recruiting 
leukocytes and effector cells to inflammatory or infectious sites (reviewed in Janeway et 
al., 2005). They have a chemoattractive function in both the innate and adaptive immune 
system. Chemokine receptors are integral membrane proteins with seven integrated helices 
that signal through a G-protein coupled mechanism. Structurally, chemokines that bind to 
a CXCR receptor contain two cysteine residues separated by amino acid and are expressed 
on a range of different cell types.   
 
The chemokine receptor, CXCR5, has been found to be expressed in elevated 
concentrations on T-bet+ CD8+ T cells (He et al., 2016). Thus, presence of this marker 
may be indicative of the presence of T-bet+ T cells. He et al. (2016) demonstrated that T-
bet+ CD8+ cells that express CXCR5 showed greater therapeutic potential than CXCR5- 
negative cells. A number of factors may contribute to this observation. First, He et al. 
demonstrated that this subset of cells was able to migrate into B cell follicles. While CD8+ 
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T cells are not frequently observed in lymphoid follicles, Valentine et al. (2019) observed 
that CXCR5+ CD8+ T cells maintain function similarly to CD4+ T cells in antibody-
mediated response to infection. Second, when He et al. administered anti-PDL1, a 
noticeable reduction in viral load was observed. Preliminary research completed using T-
bet+ CD8+ T cells has shown that this subpopulation is responsive to anti PD-L1 therapy 
(Gupta et al., 2015). Finally, assuming the marker is indicative of T-bet+ CD8+ T cells, the 
enhanced immune function may be secondary to a decrease in the number of T cells that 
have reached a stage of terminal exhaustion. In summary, quantifying expression of 
CXCR5 in cases of chronic infection can provide useful insight in observed immune 
function as well information on the amount of T-bet+ CD8+ T cells present. We expect 
CXCR5+ CD8+ cells to be increased in animals that demonstrate improved viral control.  
CD39 
Gupta et al. (2015) found CD39 is a marker of terminal, irreversible CD8+ T cell 
exhaustion in HIV. CD39 is an acidic glycoprotein which contains 24kDa of N-linked 
oligosaccharides (Kansas et al., 1991). Co-expression with PD-1 on CD8+ T cells, is a sign 
of T cell exhaustion and expression levels of the two markers have been found to be 
proportional to the viral load (reviewed in Gupta et al., 2015). I We will quantify the 
expression of both PD-1 and CD39 in order to determine the amount of exhausted CD8+ 
T cells in SIV+ rhesus macaques. Our assumption is that macaques that demonstrate better 
viral control will have lower expression of CD39, which would suggest fewer exhausted 




T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) is a glycoprotein 
that is frequently co-expressed with PD-1 on CD8+ T cells (Larsson et al., 2013; Jones et 
al., 2008). In an HIV model, Tim-3 levels were found to be up-regulated on CD8+ T cells 
which corresponded with increased viral loads and decreased concentrations of CD4+ T 
cells (Jones et al., 2008). In addition, the CD8+ Tim-3 T cells demonstrated decreased 
functionality with reduced cytokine production and proliferation. When anti-Tim-3 was 
administered, the reversal of these effects was seen. This suggests that Tim-3 serves as an 
immune checkpoint molecule that is present on exhausted CD8+ T cells. We will quantify 
Tim-3 expression in SIV+ rhesus macaques, with the expectation that macaques that 
demonstrate better viral control will have lower levels of Tim-3.  
CTLA-4 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an immunoglobulin 
protein that is expressed on activated T cells along with CD28, a costimulatory protein 
(reviewed in Larsson et al., 2013). CTLA-4 is overexpressed on CD4+ T cells in cases of 
HIV infection (reviewed in Kaufmann et al., 2007). Levels of CTLA-4 expression 
indirectly correlated with CD4+ T cell function and directly correlates with disease 
progression. An expected overall reduction in cytokine production was observed in 
subjects that overexpressed CTLA-4 on CD4+ T cells. This observation is expected 
because CD4+ T cells function in stimulating cytokine production by activating B cells and 
CTLs. Mechanistically, CTLA-4 functions by competing with CD28 to bind to T7-1 and 
TC-2 (Kaufmann et al., 2007; Graydon et al., 2019). Kaufmann et al., (2007) identified 
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increased CD4+ T cell proliferation and cytokine production when CTLA-4 was blocked. 
Currently, ipilimumab is an FDA-approved drug for metastatic melanoma that blocks the 
CTLA-4 receptor (Wei et al., 2018).  In this study, we will quantify levels of CTLA-4 in 
SIV+ rhesus macaques. Macaques demonstrating better viral control are expected to 
express lower levels of CTLA-4.  
TIGIT 
T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) is a 
marker that is found on natural killer cells, CD8+ T cells, and CD4+ T cells (Chew et al., 
2016). TIGIT was found to be overexpressed in pre- and post-ART treated individuals. 
Elevated levels of TIGIT on CD8+ T cells are believed to be indicative of T cell exhaustion. 
There was a observed decrease in CD4+ T cell counts and increased plasma viral loads 
when TIGIT was overexpressed. Additionally, TIGIT is frequently co-expressed with PD-
1 on chronically exhausted CD8+ T cells.  Administration of anti-TIGIT and anti-PD-1 
resulted in an improvement of CD8+ T cell function. In this thesis, we quantify levels of 
TIGIT in a SIV+ rhesus macaque model. We hypothesize that TIGIT will be 
downregulated in macaques that demonstrate enhanced viral control.   
TCF7 
Transcription factor 7 (TCF7) is theorized to have a critical role in maintaining T-
cell function in cases of immune cell exhaustion (reviewed in Utzschneider et al., 2016). 
Though there are a limited number of studies evaluating the function of TCF7, preliminary 
work found that T cells expressing TCF7 maintained significant proliferative capabilities. 
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As such, TCF7 may be indicative of exhausted T cells that still maintain progenitor 
capabilities (cells have not reached full state of exhaustion). Since these cells lack effector 
functionality, they are unable to directly reduce the viral load. However, the cells were able 
to produce TCF7- progenitor cells that possess effector capabilities. TCF7- progenitor cells 
are limited in their ability to expand independently. This led to the conclusion that TCF7+ 
cells have a stem cell-like function and are able to preserve proliferative potential in cases 
of chronic infection. In addition, blocking PD-1 expression in TCF7- cells can result in 
improved effector-function capabilities in these cells. These findings positively support the 
potential for TCF/PD-1 mediated therapeutic intervention in cases of chronic infection. In 
this thesis, we quantify TCF7 expression levels in SIV+ rhesus macaques. Our hypothesis 
is that macaques that are able to better control viral infection will have greater levels of 
TCF7 present. 
Lag-3 
Lymphocyte activation gene 3 (Lag-3) is an immune checkpoint molecule that can 
be found on T cells, NK cells, B cells, and plasmacytoid dendritic cells (Graydon et al., 
2019). In 1990, a preliminary study was published that addressed the functional and 
structural organization of Lag-3, a member of the immunoglobin superfamily (Triebel et 
al., 1990). This human gene is 2-kb in size. Triebel and coworkers compared the gene 
sequences that encode for Lag-3 to CD4 and found they shared similar peptidic sequences 
and intron/exon organization. In addition, both the gene encoding for Lag-3 and CD4 are 




In cases of HIV-1, Lag-3 is associated with rapid disease progression and a high 
viral load (reviewed in Graydon et al., 2019). Since Lag-3 is an immune checkpoint 
molecule, it does not directly contribute to disease progression but instead is associated 
with immune activation. However, unlike other immune checkpoint molecules that largely 
rely on an inhibitory motif to function, Lag-3 utilizes an intracellular mechanism. 
Specifically Lag-3 likely inhibits the intracellular mechanisms utilized by CD4+ T cells 
and CD8+ T cells.  
 
Additionally, elevated levels of Lag-3 were found in areas where the HIV viral 
reservoir is prominent, including lymph nodes. Blocking Lag-3 is hypothesized to reverse 
latency. Scientists have demonstrated that blocking Lag-3 for a short period of time 
resulted increased formation of memory T cells in cases of chronic viral infection. Studies 
completed using animal models have found that combined PD-1/Lag-3 blockade is more 
effective than blocking just PD-1 or just Lag-3. In this thesis, we will quantify expression 
of Lag-3 in a SIV+ rhesus macaque model. Our assumption is that lower levels of Lag-3 
will be observed in macaques that are able to better control a viral infection.  
 
Aims of Present Study 
Aim 1 
In the first part of our study, we exclusively focused on TCF-7. Our aim was to 
complete an antibody titration assay in order to identify the ideal concentrations of TCF7 
antibody that can be used to elicit a signal in a non-human primate sample. Once an ideal 
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concentration can be identified, we will quantify the amount of TCF7 present in an SIV-
infected rhesus macaque model in order to determine if TCF7 has a significant control in 
maintaining viral control. We compared TCF7 expression levels on rhesus macaques (RM) 
and human immune cells using an antibody mixture containing various dilutions of anti-
TCF7 antibody. 
Aim 2 
In the second part of our study, we evaluated the expression levels of the immune 
checkpoint and activation markers described at the end of the previous section in SIV-
infected RMs. The study population had previously been treated with two different TLR7 
agonists (GS-986 and GS-9620) and we selected two controlled and two non-controlled 
RMs from this population (Table 2). A controlled RM is a SIV positive animal that is able 
to maintain an undetectable viral load without continued therapeutic intervention (Graydon 
et al., 2019). We hypothesized that immune checkpoint markers, including PD-1, PD-L1, 
CD39, Tim-3, CTLA-4, TIGIT, and Lag-3 would be downregulated in some immune cells 
in the controlled RM population. We hypothesized that CD69, an activation marker, would 
be expressed in equal amounts on both controlled RMs and non-controlled RMs since all 
cells used in this thesis were stimulated by phytohaemagglutinin (PHA). Finally, we 
hypothesized that CXCR-5 and TCF-7, which are markers that are present on “revivable” 






Animals, SIV Challenge and Vaccination Protocol 
All (n=4) SIV-infected monkey samples used in this study were obtained from prior 
study published by Lim et al. (2018). Briefly, Indian-origin, outbred, young adult, male, 
specific pathogen–free RMs that did not express the class I alleles Mamu-A*01, Mamu-
B*08, and Mamu-B*17 (which are associated with enhanced virus control) were infected 
using a repeated low-dose intrarectal challenge with the SIVmac251 strain. The 
preformulated ART cocktail contained two reverse transcriptase inhibitors, TFV (20 
mg/ml) and FTC (50mg/ml), plus the integrase inhibitor DTG (2.5 mg/ml). This ART 
cocktail was administered once daily at 1 ml/kg body weight via the subcutaneous route. 
CD4+ and CD8+ T cell counts, CD4+/CD8+ T cell ratio, and animal weights were monitored 
regularly once or twice per week. The endotoxin-free TLR7 agonists GS-986 and GS-9620 
were provided by Gilead Science. The formulated concentrations of GS-986 and GS-9620 
administered to macaques every other week were: GS-9620 at 0.15 mg/kg and GS-986 at 
0.10 mg/kg for a total of either 7 doses (GS-9620) or 19 doses (GS-986) (Table 2). Two 
weeks after the last TLR7 dose, ART was discontinued in all groups to monitor viral 
rebound.  
For the TCF7 antibody titration assay, Stemcell Technologies (Vancouver, Canada) 
provided human leukopak obtained from healthy donors. Naïve rhesus blood samples were 
provided by Wisconsin National Primates Research Center (Madison, WI).    
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Immune cell staining and analysis 
Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll density 
gradient centrifugation from two naïve humans, two naïve RMs, two controlled RMs and 
two non-controlled RMs (Table 2) following manufacturer’s instruction (GE Healthcare 
Life Sciences, Marlborough, MA). Two controlled RMs and two non-controlled RMs were 
further stimulated with 2 µg/mL of phytohemagglutinin-M (PHA-M) in RPMI-1640 media 
supplemented with 10% heat-inactivated fetal bovine serum and 2% antibiotic cocktails 
which included penicillin and streptomycin at 37°C in a humidified 5% CO2 atmosphere 
for four days. Cells were resuspended in 1X phosphate-buffered saline (PBS) containing 
LIVE/DEAD Fixable Aqua or Blue Dead Cell Stain (Biolegend, San Diego, CA) for 
exclusion of dead cells. Human Fc-block (BD Bioscience, Franklin Lakes, NJ) was added 
to avoid non-specific Fc binding and incubated for 10 minutes at room temperature (RT) 
in the dark. Cells were first stained with fluorescent-conjugated antibody cocktails 
(addressed in Table 3) with the exception of CTLA-4 and TCF7 and then stained with 
biotin-conjugated PD-L1 (house-made, Bristol-Myers Squibb, New York, NY) followed 
by streptavidin-conjugated PE/Cy7 (BD Bioscience) at RT in the dark. Cells were washed 
once and permeabilized with TF Fix/Perm Buffer (BD Bioscience) and incubated for 50 
minutes at 4oC in the dark. The cells were washed twice with TF Perm/Wash Buffer (BD 
Bioscience) then resuspended in TF Perm/Wash Buffer containing CTLA-4 and TCF7 
antibodies for 30 minutes at RT in the dark. Cells were washed twice with TF Perm/Wash 
Buffer (BD Bioscience) prior to being fixed with 1% paraformaldehyde (ThermoFisher, 
Waltham, MA) then transferred to 5mL round-bottom tubes. Samples were run on the 
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Symphony™ flow cytometer (BD Bioscience) or LSRII™ flow cytometer. All flow 
cytometric analysis was conducted by Flowjo v. 10 (FlowJo, LLC, Ashland, OR) and 
graphical figures were generated by Prism v. 8 (GraphPad, San Diego, CA). 
Table 2: Experimental Sample Parameters 
Treatment Identifier Controlled/Non-controlled 
GS-986 (0.10 mg/kg) 280-10 Non-controlled 
344-10 Controlled 





Table 3: Antibody Panel  
Fluorescent 
Marker 
Antibody Clone Vendor Application 
FITC Lag-3 Goat polyclonal R&D Systems  
BB700 PD-1 E12.1 BD Bioscience  
PerCP/Cy5.5 CD38 CD28.2 BD Bioscience TCF7 validation 
BB790 CD45RA 549 BD Bioscience  
PE NKG2a Z199 Beckman Coulter  
PE TCF7 S33-966 BD Bioscience TCF7 validation 
PE-eF610 TIGIT MBSA43 ThermoFisher  
PE-Cy5 CXCR5 MU5UBEE ThermoFisher  
PE-Cy5.5 CD20-2H7 2H7 ThermoFisher  
BV421 CTLA-4 BNI3 BD Bioscience  
V450 CD3-SP34.2 SP34.2 BD Bioscience TCF7 validation 
BV510 CD4 L200 BD Bioscience  
BV570 CD56 HCD56 BioLegend  
BV605 CD39 TU66 BD Bioscience  
BV650 CD197 G043H7 BioLegend  
BV650 CD8 RPA-T8 BD Bioscience TCF7 validation 
BV711 CD95 DX2 BD Bioscience  
BV711 CD4 L200 BD Bioscience TCF7 validation 
BV750 VISTA MIH65.rMAb BD Bioscience  
BV786 CD28 CD28.2 BD Bioscience  
BUV396 CD45 D058-1283 BD Bioscience  
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BUV496 HLA-DR G46-6 BD Bioscience  
BUV563 CD8 RPA-T8 BD Bioscience  
BUV615 TCF7 S33-966 BD Bioscience  
BUV737 CD69 Fn50 BD Bioscience  
BUV737 CD14 M5E2 BD Bioscience TCF7 validation 
BUV805 CD14 M5E2 BD Bioscience  
APC TIM-3 344823 R&D Systems  
APC CD95 DX2 BD Bioscience TCF7 validation 
A700 CD3-SP34.2 SP34.2 BD Bioscience  









Aim 1: Antibody Validation Assay – TCF7  
Currently, there are a limited number of antibody clones commercially available 
for TCF7 for human subjects. The available antibodies are not fully validated for either 
human or RM subjects. Thus, we selected a TCF7 clone (S33-966) from BD Bioscience, 
which was originally developed as an anti-mouse antibody and has not been tested using a 
RM model. We tested this antibody clone using PBMCs from two naïve humans and two 
RMs to in order to answer a number of questions. First, we wanted to identify whether this 
clone can react with endogenous TCF7 in humans. Second, we wanted to quantify the 
optimal antibody concentration of this clone in human subjects and apply this concentration 
to a RM model. And finally, we wanted to validate the reactivity of TCF7 antibody in RM 
subjects and compare its expression level between naïve human subject and naïve rhesus 
subjects.  
 
TCF7 was originally reported to be highly expressed in naïve T memory cells 
(approximately 60-80%), medium to low expression on central memory (CM)/effector 
memory (EM) T cells (approximately 10-40%), and at undetectable levels in B cells and 
monocytes under normal physiological condition (Utzschneider et al., 2016). We first 
tested human PBMCs with several different concentrations of TCF7 (0.02 µg/mL, 0.01 
µg/mL, 0.005 µg/mL, and 0.0025 µg/mL) and included an isotype control and negative 
control (referred as Fluorescence Minus One, FMO). Using the isotype control, we were 
able to set an inclusion gate for TCF7 that did not include any background fluorescence. 
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We detected positive populations of TCF7 with all tested concentrations of TCF7. The 
isotype control and FMO did not induce significant fluorescence on either CD4+ or CD8+ 
naïve, CM, or EM cells. (Figure 1a).  
 
When testing the two highest concentrations (0.01 µg/mL and 0.02 µg/mL), a 
strong signal and clear separation of the TCF7 population on naïve and central memory 
CD4+ and CD8+ T cells was observed. Unexpectedly, when testing the two concentrations, 
we found that TCF7 was also expressed on B cells and monocytes. Utzschneider et al. 
determined these cells were not supposed to express TCF7. The positive TCF7 signals 
observed on B cells and monocytes may be attributed to non-specific binding of antibodies 
on these cells. As such, non-specific binding may also result in undesirable false positive 
signals on true target cells as well. Therefore, we determined the minimal antibody 
concentration that elicits a strong fluorescent signal and clear separation is 0.005 µg/mL 
for human subjects. Next, we tested 0.005 µg/mL of TCF7 antibody with naïve rhesus 
samples and found clear separation on CD4+ and CD8+ T memory (naïve, CM and EM) 
cells and a limited amount of background fluorescence in B cells and monocytes (Fig. 1b). 
Naïve human and naïve RM also showed similar expression levels of TCF7 in all cells 
evaluated (CD4+ naïve, CD4+ CM, CD4+ EM, CD8+ naïve, CD8+ CM and CD8+ EM) (Fig. 







Figure 1. TCF7 Antibody Panel Optimization: A. Expression of TCF7 in a human 
PBMC sample was measured using varying antibody concentrations, an isotype control, 
and a negative control (FMO). Specifically, expression was measured in B cells (CD3-
CD20+), monocytes (CD3-CD20-NKG2a+), central memory, and effector cells.  B. 
Expression of TCF7 was measured in a naïve rhesus macaque sample using 0.05 µg of the 
antibody, an isotype control, and a negative control (FMO). Specifically, expression was 
measured in B cells (CD3-CD20+), monocytes (CD3-CD20-NKG2a+), central memory, 
and effector cells.  C. Comparison of TCF7 expression in humans versus rhesus macaque 
samples, with alternating presentations of human and rhesus macaque graphs. Closed 
circles are indicative of each individual subject and a horizontal line marks the average of 
the two subjects. 
 
Table 4: Average TCF7 Expression Levels in a Human Sample  
(% of total cell population) 
 
Table 5: Average TCF7 Expression Levels in a Rhesus Macaque Sample (% - Percent) 
 
  
Human Rhesus Human Rhesus 
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Aim 2: Controlled versus non-controlled immune checkpoint expression  
An optimized antibody panel (Table 3) was applied to isolated PBMC samples 
obtained from two non-controlled and two controlled TLR7 treated RMs. The lymphocyte 
population was first gated based on its size and granularity (Figure 2), then immune cells 
were defined as follows; CD4+ T cells (CD3+CD4+CD14-CD20-CD45+NKG2a-), CD8+ T 
cells (CD3+CD8+CD14-CD20-CD45+NKG2a-), B cells (CD45+CD3-CD14-CD20+NKG2a-
), NK cells (CD45+CD3-CD14-CD20-CD8+NKG2a+).  
CD69 
The average percent difference in expression level of CD69 on B cells is 22.95% 
greater in controlled RMs (Fig. 3a, Table 6 and 7) compared to non-controlled RMs. 
Additionally, there is an average increase of 3.05% of CD69 on CD4+ T cells as well on 
CD8+ T cells (>1.4%) in controlled groups. This marker was found on over 90% of NK 
cells in both controlled and non-controlled RMs at 94.7% and 96.9% of the total cell 
population respectively.  
CD39 
The greatest expression of CD39 was found on CD8+ T cells with nearly identical 
expression found on controlled (65%) and non-controlled RMs (65.2%) (Fig. 3b, Table 6 
and 7). Expression patterns in controlled and non-controlled samples were similar in NK 
cells with an expression level of approximately 25% in each sample. CD39 was expressed 
in greater frequency on CD4+ T cells in non-controlled RMs, with an average difference of 
6.35%. However, when comparing the two non-controlled RMs, we found that subject 280-
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10 expressed approximately 32.1% more of this marker which may have upwardly skewed 
the non-controlled data average. B cells obtained from controlled RMs expressed 27.43% 
more CD39 than non-controlled RMs (Fig. 3b).  
CXCR5 
90.15% of B cells express CXCR5 in controlled RMs with an average difference of 
10.2% in expression levels between the controlled and non-controlled samples (Fig. 3c, 
Table 6 and 7). In addition, CD4+ T cells in controlled RMs expressed an average of 
19.35% more CXCR5 than non-controlled RMs. Expression levels of CXCR5 on CD8+ T 
cells was 1.565% greater in the controlled population. There was a minimal difference in 
CXCR5 expression in NK cells, with the non-controlled RMs expressing an average of 
0.985% CXCR5 more than the controlled RMs.  
TCF7 
TCF7 levels are expressed in greater frequency on CD4+ T cells obtained from our 
controlled sample compared to that seen in non-controlled RMs, with an average difference 
of 20.5% (Fig. 3d, Table 6 and 7). Additionally, expression levels of TCF7 are elevated 
in CD8+ T cells in controlled RMs with an average difference of 14.35% between the 
controlled and non-controlled samples. NK cells from controlled RMs presented with an 
average of 11.3% more TCF7 than non-controlled RMs. Finally, the presentation on B cells 







CD4+ T cells, CD8+ T cells, and B cells from controlled RMs all expressed lower 
levels of PD-1 than that of the non-controlled population (Fig. 3e, Table 6 and 7). Non-
controlled RMs had a higher expression overall of PD-1 on CD4+ T cells (16.45%), CD8+ 
T cells (0.5%), and B cells (8.05%). While NK cells expressed 1.05% more PD-1 in 
controlled RMs, the overall concentration of PD-1 on both controlled and non-controlled 
RMs was low with an average expression of 6.43% in the non-controlled population and 
an average of 7.48% in the controlled population.  
PD-L1 
Non-controlled RMs generally expressed a greater frequency of PD-L1 than that of 
controlled RMs which shared similar expression tendencies as PD-1 (Fig. 3f, Table 6 and 
7). Non-controlled RMs showed higher expression of PD-1 on NK cells and CD8+ T cells 
with an average of 32.15% and 14.95% more than what was seen in the controlled 
population. The difference in expression levels on CD4+ T cells was relatively small in 
comparison, with non-controlled RMs expressing an average of 3.25% more PD-L1 than 
controlled RMs. Interestingly, the controlled B cell sample did express a greater overall 
concentration of PD-L1than that of non-controlled sample, with an increase of 3.6% in 




TIGIT was expressed in greater frequency on NK cells, CD4+ T cells, CD8+ T cells 
(16.295%, 7.45%, and 4.6%) in controlled RMs (Fig. 3g, Table 7). Non-controlled RMs 
expressed an average of 1.03% more TIGIT on B cells than cells obtained from the 
controlled sample.  
CTLA-4 
CTLA-4 was present in elevated frequencies in all controlled RM immune cells 
when compared to cells from non-controlled samples (Fig. 3h). CD4+ T cells expressed an 
average of 15.3% more CTLA-4 in controlled RMs than that of non-controlled RMs. 
Similarly, CD8+ T cells from controlled RMs expressed an average of 13.65% more 
CTLA-4 than non-controlled RMs. Controlled RM B cells expressed an average of 10.3% 
more CTLA-4 than non-controlled B cells. Finally, NK cells expressed 1.86% more CTLA-
4 in controlled RMs than non-controlled RMs.  
Tim-3  
Overall, the difference in expression levels of Tim-3 between controlled and non-
controlled RMs in the immune cells studied were minimal. CD4+ T cells and B cells 
expressed greater concentrations of the marker in controlled RMs than non-controlled RMs 
(0.1575% and 1.085%) (Fig. 3i, Table 6 and 7). CD8+ T cells obtained from non-
controlled RMs expressed marginally more Tim-3 with an average increased expression of 





CD4+ T cells, CD8+ T cells, and NK cells expressed slightly more Lag-3 in non-
controlled RMs than controlled RMs (0.055%, 0.19%, and 0.355% respectively) (Fig. 3j, 
Table 6 and 7). B cells expressed more Lag-3 in the controlled RM population than the 




Figure 2. Gating Strategy:  
Isolated PBMC samples were gated 
using the pictured protocol. Doublets 
were excluded from our study. Live 
cells were identified using live-dead 
aqua. Lymphocytes were isolated 
from the live cell population and were 
further subdivided into CD3-
CD20dim, CD3-CD20+, and CD3+ 
cells. NK cells were separated from 
the CD3- population, co-expressing 
NKG2a and CD8. CD8+ and CD4+ 
cells were identified from the 
CD3+CD14-NKG2a- cells. Finally, 
both the CD8+ and CD4+ cells were 
divided into naïve cells, central 







































Figure 3. Immune Checkpoint Expression Levels in TLR7 treated ART-suppressed 
Rhesus Macaques: Immune checkpoint expression levels obtained via flow cytometric 
analysis of the following activation and immune checkpoint markers: a. CD69 b. CD39 c. 




Table 6: Average expression levels of immune checkpoint markers in a controlled 






CD4+ T cells CD8+ T cells NK cells B cells
CD69 Non-controller 28 28.6 96.9 19.75
Controller 31.05 30 94.7 42.7
CD39 Non-controller 37.65 65.2 25.3 10.07
Controller 31.3 65 25.545 37.5
CXCR5 Non-controller 12.65 2.61 2.455 79.95
Controller 32 4.175 1.47 90.15
TCF7 Non-controller 30.55 4.245 50.2 0.695
Controller 51.05 18.595 61.5 4
PD-1 Non-controller 80.1 36.6 6.43 20.55
Controller 63.65 36.1 7.48 12.5
PD-L1 Non-controller 61.35 53.55 66.75 63.3
Controller 58.1 38.6 34.6 66.9
TIGIT Non-controller 26.4 21.95 26.155 4.93
Controller 33.85 26.55 42.45 3.9
CTLA4 Non-controller 66.15 64.5 14.71 3.285
Controller 81.45 78.15 16.57 13.585
Tim-3 Non-controller 0.1225 0.475 0 1.59
Controller 0.28 0.43 0 2.675
Lag-3 Non-controller 1.125 0.91 1.18 3.065




Table 7: Differences between the average expression levels of immune checkpoint 


























CD4+ T cells CD8+ T cells NK cells B cells
CD69 3.05 1.4 -2.2 22.95
CD39 -6.35 -0.2 0.245 27.43
CXCR5 19.35 1.565 -0.985 10.2
TCF7 20.5 14.35 11.3 3.305
PD-1 -16.45 -0.5 1.05 -8.05
PD-L1 -3.25 -14.95 -32.15 3.6
TIGIT 7.45 4.6 16.295 -1.03
CTLA4 15.3 13.65 1.86 10.3
Tim-3 0.1575 -0.045 0 1.085




Due to the limited number of TCF-7 antibody clones available for human and RM 
models, we first attempted to determine an optimal TCF7 antibody concentration that will 
elicit a signal in a non-human primate sample. Once the optimal concentration was 
identified, we quantified the amount of TCF7 present in controlled and non-controlled 
RMs. Additionally, we identified the expression levels of a number of immune checkpoint 
and activation molecules and compared expression levels between controlled and non-
controlled RMs to have better understanding of the role of immune checkpoints and 
HIV/SIV pathogenesis.  
 
An antibody titration assay was performed to determine the optimal concentration 
of TCF-7 antibody for use in flow cytometry analysis to quantify TCF7 expression in 
controlled and non-controlled RMs. We found the optimal concentration in humans was 
0.05 µg and continued to use this concentration throughout our study. Analysis of obtained 
data indicated that at 0.05 µg concentration, TCF7 was predominantly expressed on CD4+ 
and CD8+ naïve cells. Both human and rhesus macaques showed similar expression levels 
of TCF7 on each memory subtype of CD4+ and CD8+ T cells. This supported data obtained 
by Utzschneider et al, who identified TCF7 expression on CD4+ and CD8+ naïve T cells 
to be approximately 90% (Utzschneider et al., 2016). We were then able to use our 
validated TCF-7 antibody to identify expression in controlled and non-controlled RMs. It 
is hypothesized that TCF-7 has an important role in maintaining T cell function in cases of 
immune exhaustion. Specifically, it is believed that cells expressing this marker possess 
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“progenitor-like” properties and are able to function in proliferating the immune response 
in cases of chronic infection. This theory was supported by the data obtained in our study, 
with controlled RMs expressing more TCF-7 on CD4+ and CD8+ T cells than non-
controlled RMs.  
 
We evaluated the expression levels of two activation markers, CD69 and CD39, in 
CD4+ T cells, CD8+ T cells, NK cells, and B cells. Our objective was to identify differences 
in activation between controlled RMs and non-controlled RMs after antigenic re-
stimulation. CD69 has been identified as a general immune activation marker for T, B, and 
NK cells (Janeaway et al., 2005). Additionally, CD69 acts as a co-stimulatory molecule on 
T cells resulting in enhanced proliferation and function (Borrego et al., 1999). CD39 is also 
an activation marker in lymphocytes, predominantly on B cells, and it has a key role in 
immunoglobulin class switch recombination (Schena et al, 2013). On average, the 
controlled RMs expressed more CD69 on CD4+ T cells (3.05%), CD8+ T cells (1.4%), and 
NK cells (2.2%). Since the difference in expression levels of the CD69 marker is marginal 
between the two study subsets, there is likely a similar level of activation in controlled and 
non-controlled RMs. Strikingly, CD69 and CD39 were found to be expressed in higher 
concentrations on B cells in the controlled group when compared to the non-controlled 
RMs which may be indicative of a greater number of active B cells producing antibodies 




We then evaluated the expression levels of several immune checkpoint molecules 
including PD1, PDL1, CTLA4, and TIGIT. Previous research has shown that these four 
markers are indicative of HIV-mediated T cell exhaustion and rapid viral progression 
(Boyer et al, 2018; Wykes et al, 2018). Our data showed an overall decrease of PD-1 and 
PD-L1 in CD4+ T cells, CD8+ T cells, and NK cells in controlled RMs. In contrast, the 
expression levels of CTLA-4 and TIGIT increased in controlled RMs. As such, it is likely 
that TIGIT and CTLA-4 do not contribute to overall viral control while PD-1 and PD-L1 
have a more substantial role in viral control mediated by TLR7 treatment. Of interest, 
subjects treated with GS-9620 analog showed a greater decrease in expression of PD-1 and 
PD-L1 in the controlled population. This is likely secondary to structural differences 
between the GS-986 analog and GS-9620 agonist. Additionally, one RM from the GS-9620 
treatment group presented with the lowest level of expressed PD-1. A previous study 
conducted using this subject showed lower levels of viral SIV RNA overall post-ART 
treatment (Lim et al., 2018) which may indicate that this subject is intrinsically better at 
controlling a viral infection (Appendix I, Fig. 4). 
 
CXCR5 is expressed in high concentrations on cells that typically reside in the 
center of lymphoid aggregates near inflamed tissue (Rao et al, 2018). These cells are known 
as T follicular helper (Tfh) cells and are characterized by the surface expression of several 
markers, including CXCR5, PD1, and ICOS (Rao et al, 2018).  The CXCR5 present on Tfh 
cells will ligate with CXCL13 ultimately resulting in B cell differentiation and antigen 
production in lymphoid organs (Locci et al., 2013). Cagigi et al. (2008) reported that HIV+ 
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individuals express a lower amount of CXCR5 on B cells due to a decreased concentration 
of CD4+ T cells. Our data shows increased expression of CXCR5 on CD4+ T cells in 
controlled RMs when compared to non-controlled RMs, with an average increase of 
10.35%. This may be indicative of an increase in functional CD4+ Tfh-like cell and 
improved viral control. One RM from the controlled group presented with the greatest 
concentration of CD4+ CXCR5 (40.9%). 
 
In conclusion, we found controlled RMs showed lower expression of PD-1 and PD-
L1 on several immune cells, particularly NK and T cells, which are responsible for 
controlling viremia and inducing an optimal immune response. Additionally, controlled 
RMs showed higher expression of activation markers on B cells, as well as an increase of 
CXCR5 on CD4+ T cells. Thus, there may be a connection between functional B cell 
activation and improved viral control. An important factor to consider while reviewing the 
results from this study is the number of study subjects that were analyzed (n=4). We 
recommend repeating this study with a larger number of subjects to obtain more precise 
insights and statistically significant results. Additionally, we did notice lower overall 
expression levels of Tim-3 and Lag-3 in our panel. While the exact reason for this is 
unknown, we believe that it may be secondary to the quality of the antibody that was used. 
Replicating this experiment with Tim-3 and Lag-3 antibodies obtained from a different 










Figure 4. SIV RNA Rebound Kinetics in SIV-Infected RMs After ART Cessation: 
Viral rebound kinetics after stopping ART in groups of RMs treated with eitherGS-986 
(0.1 mg/kg; n =3; blue) or GS-9620 (0.15 mg/kg; n =3; black). Log plasma virus RNA was 
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